Home » interviews » Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Founder & CEO, Sapala Organics

Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Founder & CEO, Sapala Organics

Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Sapala Organics

  • November 24, 2025

Interviews

Only 4-5 I
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 I
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
View More

Appointments

Shyamakant Giri resigns as CEO of Gland Pharma
Shyamakant Giri resigns as CEO of Gland Pharma
Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access
Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access
Boehringer Ingelheim India appoints Meenal Gauri as Managing Director
Boehringer Ingelheim India appoints Meenal Gauri as Managing Director
View More

Startup

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups
EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups
Teva launches 'Teva Rise' to harness global innovation and transform healthcare
Teva launches 'Teva Rise' to harness global innovation and transform healthcare
View More

Digitization

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
PharmEasy integrates with Samsung Health to streamline digital healthcare
PharmEasy integrates with Samsung Health to streamline digital healthcare
Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI
Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI
View More

Latest Stories

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

Opinion
Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Metal-free catalysis is transforming future of sustainable pharmaceutical innovation
Metal-free catalysis is transforming future of sustainable pharmaceutical innovation

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging